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MaOBJECTIVES This study performed a contemporary systematic review and meta-analysis of exercise-based cardiac
rehabilitation (ExCR) for heart failure (HF).
BACKGROUND There is an increasing call for trials of models of ExCR for patients with HF that provide alternatives to
conventional center-based provision and recruitment of patients that reﬂect a broader HF population.
METHODS The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, and PsycINFO
databases were searched between January 2013 and January 2018. Randomized trials comparing patients undergoing
ExCR to control patients not undergoing exercise were included. Study outcomes were pooled using meta-analysis.
Metaregression examined potential effect modiﬁcation according to ExCR program characteristics, and risk of bias, trial
sequential analysis (TSA), and Grading of Recommendations Assessment Development and Evaluation (GRADE) were
applied.
RESULTS Across 44 trials (n ¼ 5,783; median follow-up of 6 months), compared with control subjects, ExCR did not
reduce the risk of all-cause mortality (relative risk [RR]: 0.89; 95% conﬁdence interval [CI]: 0.66 to 1.21; TSA-adjusted
CI: 0.26 to 3.10) but did reduce all-cause hospitalization (RR: 0.70; 95% CI: 0.60 to 0.83; TSA-adjusted CI: 0.54 to 0.92)
and HF-speciﬁc hospitalization (RR: 0.59; 95% CI: 0.42 to 0.84; TSA-adjusted CI: 0.14 for 2.46), and patients reported
improved Minnesota Living with Heart Failure questionnaire overall scores (mean difference: 7.1; 95% CI: 10.5
to 3.7; TSA-adjusted CI: 13.2 to 1.0). No evidence of differential effects across different models of delivery, including
center- versus home-based programs, were found.
CONCLUSIONS This review supports the beneﬁcial effects of ExCR on patient outcomes. These beneﬁts appear to be
consistent across ExCR program characteristics. GRADE and TSA assessments indicated that further high-quality
randomized trials are needed. (J Am Coll Cardiol HF 2019;7:691–705) © 2019 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2019.04.023
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692C hronic heart failure (HF) representsa major health issue that affects 1%to 2% of adults in the Western world
(1,2). Whereas survival after HF diagnosis has
improved, prognosis remains poor; 30% to
40% of patients die within 1 year of diagnosis
(1,2). Patients living with HF experience
marked reductions in their exercise capacity,
which has detrimental effects on their activ-
ities of daily living and health-related quality
of life (HRQoL) (3,4).
Meta-analyses of randomized trials over
the last decade support the Class I recom-SEE PAGE 706mendation of current national and international
clinical guidelines that exercise-based cardiac reha-
bilitation (ExCR) should be offered to all patients with
HF (5–7). However, the authors of the 2014 Cochrane
ExCR review raised concerns about the generaliz-
ability of their meta-analysis results given that trial
participants were predominantly lower-risk male pa-
tients who had HF with reduced ejection fraction (8).
Furthermore, recent surveys show that <10% of
patients with HF in the United States and <20% inE 1 Summary of the Study Selection Process
ardiac rehabilitation; RCT ¼ randomized control trial.Europe participated in ExCR (9,10), prompting a call to
explore more accessible alternatives to the conven-
tional model of group supervised center-based ExCR,
such as home-based and internet programs (8,9).
The present study undertook a review and meta-
analyses of an updated Cochrane database in order
to reassess the evidence base for ExCR in patients
with HF, including recently performed randomized
clinical trials. The updated review includes analysis
of center-based compared to home-based programs.
This update incorporates both a formal assessment of
overall trial quality using the Grading of Recommen-
dations Assessment, Development and Evaluation
(GRADE) guidelines and trial sequential analysis
(TSA) to control for type I and type II errors of con-
ventional meta-analysis methods (11).METHODS
This systematic review was conducted and reported
in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)•
•
•
•
•
•
•
•
•
•
TABLE 1 Summary of Trial, Patient, and Intervention Characteristics
All Trials
(N ¼ 44)
Trials Published
2015-2018
(n ¼ 10)
Publication year
1990-1999 5 (11) -
2000-2009 22 (50) -
2010 onward 17 (39) 10 (10)
Study location
Europe 26 (59) 5 (50)
North America 12 (27) 1 (10)
Other 6 (14) 4 (40)
Single center 38 (86) 7 (70)
Sample size 59 (19-2,331) 61 (27-343)
Population characteristics
Sex
Males 13 (30) 1 (10)
Females 0 (0) 0 (0)
Both males and females 33 (75) 9 (90)
Not reported 1 (2) 0 (0)
Age, yrs 63 (51-81) 67 (56-77)
Diagnosis
Ejection fraction, % 32 (21-49) 36.5 (34-49)
HFpEF included† 6 (14) 3 (30)
Not reported 7 (16) 4 (40)
NYHA functional class IV included 7 (16) 1 (10)
Not reported 14 (31) 5 (50)
Intervention characteristics
ExCR type
Exercise-only programs 31 (68)‡ 7 (70)
Comprehensive programs 14 (32)‡ 3 (30)
Exercise type
Aerobic only 32 (73) 10 (100)
Aerobic and resistance 12 (27) 0 (0)
Dose of exercise
Duration, months 6 (2–30) 6 (2–8)
Frequency, sessions/week 1-7 1-3
Length, min/session 10-120 30-60
Intensity
Maximal heart rate, % 40–80 40–80
Maximal oxygen uptake, % (VO2max) 50–85 60–70
Borg rating 11-18 6-20
Setting
Center-based only 21 (47)* 5 (45)*
Both center- and home-based 14 (31) 2 (18)
Home-based only 9 (20)* 4 (36)*
Not reported 1 (2) 0 (0)
Duration of follow-up, months 6 (6-74) 6 (6-62)
Values are n (%) or median (range). Median of study means the study includes both exercise-only
and comprehensive cardiac rehabilitation arms. *Includes 1 trial that had both separate center-
based and home-based only arms. †Stated that patients with ejection fraction >40% or with
diastolic HF included. ‡Includes 1 trial that had both separate exercise and comprehensive
rehabilitation arms.
CHD ¼ coronary heart disease; ExCR ¼ exercise-based cardiac rehabilitation; HFpEF ¼ heart
failure with preserved ejection fraction; NYHA ¼ New York Heart Association.
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693statement and the Cochrane Handbook for Interven-
tional Reviews (12–14).
DATA SOURCES AND SEARCHES. Databases (Cochrane
Central Register of Controlled Trials [CENTRAL],
MEDLINE, EMBASE, CINAHL, and PsycINFO) were
searched from January 2013 (the end date of the
Cochrane 2014 review) to January 2018, without
language restriction. Web of Science, bibliographies
of systematic reviews, trial registers (e.g., the World
Health Organization International Clinical Trials
Registry Platform and the Clinical Trials.gov) were
also checked, in addition to reference lists of all
eligible studies and other published systematic re-
views. A copy of the search strategy is available on-
line (Online Appendix 1).
STUDY SELECTION. Studies were eligible, as follows,
if they were: 1) randomized trials with $6 months
follow-up; 2) had enrolled adult subjects (>18 years of
age) with evidence of HF with reduced ejection frac-
tion and HF with preserved ejection fraction; 3)
compared ExCR interventions, either alone or as a
component of a comprehensive ExCR program (plus
education and/or psychological intervention); 4)
included a control group that must not have received
exercise training but might have received education,
psychological intervention, or usual medical care
alone; and 5) reported 1 or more of the following
outcome measurements: mortality (all-cause and HF-
related), hospitalization (all-cause or HF-related
hospitalization), or HRQoL.
DATA EXTRACTION AND RISK OF BIAS ASSESSMENT.
Trial information was extracted across studies. Study
risk of bias was assessed using Cochrane standard
criteria (14).
Study selection, data extraction, and risk of bias
assessment were carried out independently by 2 au-
thors. Any disagreements were resolved by
consensus, and decisions were independently
checked by a third author.
DATA ANALYSIS AND EVIDENCE GRADING. Heter-
ogeneity was explored among the studies qualita-
tively (by comparing the study characteristics) and
quantitatively (using the chi-square test of hetero-
geneity and I2 statistic). Where appropriate, an over-
all estimate of treatment effect was obtained for
combining the results from included studies for each
outcome. A random-effects model was used where
there was formal evidence of statistical heterogeneity
(i.e., chi-square test p value <0.10 and an I2 statistic
>50%). For outcomes with lower levels of statistical
heterogeneity, both ﬁxed-effects and random-effects
models were applied, reporting ﬁxed-effects results
unless there were differences in statistical inference,where the most conservative random-effects model
was reported. Where reported, outcome results were
pooled at 2 time points: up to 12 months follow-up
and >12 months follow-up.
TABLE 2 Summary of Risk of Bias Assessment
Low Risk of
Bias
Unclear Risk of
Bias
High Risk of
Bias
Random sequence generation (selection bias) 16/44 (36) 27/44 (61) 1/44 (3)
Allocation concealment (selection bias) 10/44 (23) 34/44 (77) 0/44 (0)
Blinding of outcome assessment (detection bias) 16/44 (36) 25/44 (57) 3/44 (7)
Incomplete outcome data (attrition bias) 37/44 (84) 3/44 (7) 4/44 (9)
Selective reporting (reporting bias) 37/44 (84) 6/44 (14) 1/44 (3)
Groups balanced at baseline 40/44 (91) 2/44 (5) 2/44 (5)
Intention-to-treat analysis conducted 39/44 (89) 4/44 (9) 1/44 (3)
Groups received same treatment (apart
from the intervention)
33/44 (77) 11/44 (23) 0/44 (0)
Values are n/N (%).
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694Random effects metaregression was used to
examine the association between the effect of exer-
cise on all-cause mortality, all-hospitalization, and
HRQoL (e.g., using Minnesota Living with
Heart Failure [MLWHF] or other measurements) up to
12 months (15). Covariates included dose of aerobic
exercise (calculated as the overall number of weeks of
training multiplied by the mean number of sessions
per week multiplied by the mean duration of sessions
in minutes); type of exercise (aerobic training alone
or aerobic plus resistance training); setting (center
only, home only, both center and home); type of
rehabilitation (exercise only compared to compre-
hensive); overall risk of bias (where “low risk” of bias
occurred on $5 of 8 items compared to “high risk” of
bias which occurred on <5 of 8 items); single-center
compared to multicenter; and publication date.
Given the relatively small trial-to-covariate ratio,
metaregression was limited to univariate analysis
(14). This study sought to explore small-study bias
and the potential for publication bias by using funnel
plots and the Egger test (16). Meta-analysis results are
presented stratiﬁed by risk of bias. Two post hoc
sensitivity analyses were undertaken to examine,
ﬁrst, the measured impact of excluding trials that
included diastolic/preserved ejection fraction pa-
tients with HF, and second, the measured impact of
excluding the large HF-ACTION (Participants in Heart
Failure: A Controlled Trial Investigating Outcomes of
Exercise Training trial (17). Analyses were performed
using RevMan version 5.2 software (Chocrane,
London, United Kingdom) and STATA version 15.0
software (College Station, Texas). GRADE guidelines
and TSA analysis methods are summarized in Online
Appendixes 2 and 3, respectively.
RESULTS
DESCRIPTION OF STUDIES. The 2014 version of the
Cochrane review contributed 33 trials (8). Searchesfor this update yielded 12,944 titles, of which 92 full-
length papers were considered for inclusion. This
updated review identiﬁed 11 new trials (see citations
in Online Appendix 4) in a total of 1,092 patients and
included a total of 44 trials. The study selection
process is summarized in Figure 1. Four trials (18–21)
included more than 1 comparison between patients
with ExCR and control subjects, resulting in a total of
48 ExCR-versus-control comparisons.
STUDY, PATIENT, AND INTERVENTION CHARACTERISTICS.
The included trials randomized a total of 5,783 pa-
tients, predominantly those with HF with reduced
ejection fraction and New York Heart Association
functional classes II and III (Table 1). Eight trials
formally stated that they included patients with HF
with preserved ejection fraction (deﬁned as either an
ejection fraction of >40% or a diagnosis of diastolic
HF) (18,22–28). The median follow-up was 6 months,
and 6 studies reported $12 months of follow-up. Most
studies were small in sample size (median: n ¼ 52),
with 1 large multicenter trial (HF-ACTION) (17)
contributing w40% of all participants. The median
age of participants across studies was 63 years old.
Although 33 studies (75%) included women, the me-
dian proportion of women recruited was only 19%.
More recent studies (published from 2013 to 2018)were
more likely to recruit participants who were older, fe-
male, and had HF with preserved ejection fraction.
ExCR programs were typically delivered in a su-
pervised hospital or center-based setting, either
exclusively or in combination with some maintenance
home-exercise sessions. Nine studies were conducted
in an exclusively home-based setting (18,20,24,28–34).
Whereas the primary mode of exercise training across
all studieswas aerobic, the overall or average duration,
frequency, and intensity of sessions varied consider-
ably across studies. Approximately two-thirds of trials
were exercise-only programs. The control group of
included studies received no formal exercise training
but included a wide range of interventions. These in-
terventions included education, psychological in-
terventions, and usual medical care alone.
RISK OF BIAS ASSESSMENT. Several trials failed to
give details sufﬁcient to allow complete assessment
of their potential risk of bias. Details of generation
and concealment of random allocation sequences and
blinding of outcomes were particularly poorly re-
ported (Table 2). However, the other 5 items (incom-
plete outcome data, selective reporting, groups
balanced at baseline, intention-to-treat analysis con-
ducted, and groups who received the same treatment
apart from the ExCR intervention) were generally
judged to be at low risk of bias. There was no
CENTRAL ILLUSTRATION Summary of Meta-Analysis Effects on Clinical and Health-Related
Quality of Life Outcomes
n Trials
(n
comparisons)
27 (28)
6 (6)
67/1,302
244/1,418
75/1,294
280/1,427
RR: 0.89
(0.66-1.21)
RR: 0.88 
(0.75-1.02)
I2 = 0%; 
p = 0.97
I2 = 34%;
p = 0.18
Low*†
High
21 (21)
6 (7)
180/1,093
772/1,348
258/1,089
825/1,343
RR: 0.70
(0.60-0.83)
RR: 0.70
(0.47-1.05)
I2 = 19%;
p = 0.22
I2 = 66%;
p = 0.007
Moderate‡
Very
low ||¶
Outcome
All-cause
mortality
6-12 months
follow-up
All-cause 
mortality 
≥12 months 
follow-up
All-cause
hospitalization
6-12 months
follow-up
All-cause 
hospitalization 
≥12 months 
follow-up
14 (15) 40/562 61/552
RR: 0.59
(0.42-0.84)
I2 = 11%;
p = 0.32
Low†‡
HF-related
hospitalization
6-12 months
follow-up
17 (18)
3 (3)
- -
- -
MD: −7.1
(−10.5 to −3.7)
MD: −9.5
(−17.5 to −1.5)
I2 = 82%;
p < 0.0001
I2 = 73%;
p < 0.03
Low†#
Low††***
MLWHF
6-12 months
follow-up
MLWHF 
≥12 months 
follow-up
27 (29) - -
SMD:
−0.60
(−0.82 to −0.39)
I2 = 87%;
p < 0.0001
Low†**
All HRQoL
outcome
6-12 months
follow-up
Number
of ExCR
patient events/
total
patients
Control 
(Number of 
control patient 
events/total
patients)
Mean
Treatment
Effect
(95% CI)
Statistical
Heterogeneity
(I2 statistic;
chi-square
p value)
GRADE
Quality
Rating
Taylor, R.S. et al. J Am Coll Cardiol HF. 2019;7(8):691–705.
*Some concerns arose with random sequence generation and allocation concealment; bias likely, therefore the quality of evidence was downgraded by 1 level.
†Imprecise due to small numbers of events (<300); therefore, certainty of evidence was downgraded by 1 level. ‡Some concerns appeared with random sequence
generation, allocation concealment, and blinding of outcome assessment; bias likely, therefore, certainty of evidence was downgraded by 1 level. kInconsistent
directions of effect and substantial statistical heterogeneity (I2 ¼ 66%); therefore, certainty of evidence was downgraded by 1 level. ¶Imprecise due to conﬁdence
intervals, including potential for no beneﬁt and important beneﬁt, as 95% CI crosses RR of 0.75; therefore, certainty of evidence was downgraded by 1 level.
#Inconsistency with considerable statistical heterogeneity (I2 ¼ 82%); therefore, certainty of evidence was downgraded by 1 level. **Inconsistency with considerable
statistical heterogeneity (I2 ¼ 87%); therefore, certainty of evidence was downgraded by 1 level. ††Inconsistency with substantial statistical heterogeneity (I2 ¼ 73%);
therefore, certainty of evidence was downgraded by 1 level. §§Imprecise due to small number of participants (<400); therefore, certainty of evidence was
downgraded by 1 level. ***Some concerns with random sequence generation, allocation concealment, and groups balanced at baseline; bias likely, therefore,
certainty of evidence was downgraded by 1 level. CI ¼ conﬁdence interval; ExCR ¼ exercise-based cardiac rehabilitation; GRADE ¼ Grading of Recommendations
Assessment, Development and Evaluation; HRQoL ¼ health-related quality of life; MD ¼ mean difference; RR ¼ relative risk; SMD ¼ standardized mean difference;
MLWHF: Minnesota Living with Heart Failure questionnaire; RR ¼ relative risk.
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FIGURE 2 Meta-Analyses of Events and HRQoL Outcomes
(A) All-cause mortality at 6- to 12-months’ follow-up. (B) All-cause mortality at >12 months’ follow-up. (C) Hospital admissions at 6- to 12-months” follow-up. (D) All-
cause hospital admissions at >12 months’ follow-up. (E) HF-speciﬁc hospital admissions. (F) MLWHF at #12 months’ follow-up. (G) All HRQoL scales at #12 months’
follow-up. (H) MLWHF at >12 months’ follow-up.
Continued on the next page
Taylor et al. J A C C : H E A R T F A I L U R E V O L . 7 , N O . 8 , 2 0 1 9
Cochrane Review Update: Rehabilitation for Heart Failure A U G U S T 2 0 1 9 : 6 9 1 – 7 0 5
696
FIGURE 2 Continued
B
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697evidence that trials published from 2013 to 2018 were
overall better reported than those published before
2013 (20 of 34 trials [69%] with $5 items published
before 2013 were judged to be of low bias compared to
7 of 10 trials [70%] published between 2013 and later).
OUTCOMES AND GRADE ASSESSMENT. Outcome re-
sults are summarized in the Central Illustration and
discussed later.
Morta l i ty . There were no signiﬁcant differences in
total mortality up to 12 months follow-up between the
ExCR and control groups (ﬁxed-effects, 27 trials, 28
comparisons, n ¼ 2,596: relative risk [RR]: 0.89; 95%
conﬁdence interval [CI]: 0.66 to 1.21) (Figure 2A) (low
certainty). The GRADE rating was downgraded due to
high risk of bias and imprecision (number of
events: <300).
ExCR versus control did not affect mortality with
>12 months follow-up (ﬁxed-effects, 6 trials/com-
parisons, n ¼ 2,845: RR: 0.88; 95% CI: 0.75 to 1.02)
(Figure 2B) (high certainty). Studies did not consis-
tently report deaths due to HF or sudden death.
At 20% relative risk reduction (RRR), the trial
sequential analysis (TSA)-adjusted CI was 0.26 to
3.10 for mortality to 12 months follow-up and 0.67 to
1.14 for mortality at >12 months (Online Appendix 5).
In both cases, the z-curve did not cross the
conventional CON and TSMB boundaries(Online Figures 1.1c and 1.2c). In conclusion, the total
sample size in the meta-analysis was underpowered
to identify a difference in mortality with patients
with ExCR compared with control participants in
both short- and long-term follow-up.
Hosp i ta l admiss ions . Overall hospital admissions
(ﬁxed-effect, 21 trials/comparisons, n ¼ 2,218: RR:
0.70; 95% CI: 0.60 to 0.83) (Figure 2C) (GRADE
showed moderate certainty) up to 12 months follow-
up were reduced with ExCR compared with control
with an associated reduction in HF-speciﬁc hospital-
izations (ﬁxed effect, 14 trials, 15 comparisons, n ¼
1,114: RR: 0.59; 95% CI: 0.42 to 0.84) (Figure 2D) (low
certainty). The 6 trials (7 comparisons, n ¼ 2,691) with
>12 months follow-up showed weak evidence of a
reduction in overall hospital admissions (random ef-
fects, RR: 0.70; 95% CI: 0.47 to 1.05) (Figure 2E, very
low certainty). The GRADE rating was downgraded
due to high risk of bias, inconsistency, and
imprecision.
At 20% RRR, the TSA-adjusted CI was 0.54 to 0.92
for all-cause hospitalization up to 12 months, 0.14 to
2.46 for all-cause hospitalization >12 months, and
0.14 to 3.56 for HF-speciﬁc hospitalization (Online
Table 3, Online Figures 1.3c, 1.4c, and 1.5c). This ef-
fect was lost when limited to trials at low risk of bias
(Online Figure 1.3e).
FIGURE 2 Continued
C
Continued on the next page
Taylor et al. J A C C : H E A R T F A I L U R E V O L . 7 , N O . 8 , 2 0 1 9
Cochrane Review Update: Rehabilitation for Heart Failure A U G U S T 2 0 1 9 : 6 9 1 – 7 0 5
698Health-re lated qual i ty of l i fe . A total of 28 trials
assessed HRQoL by using a range of validated generic
or disease-speciﬁc outcomemeasurements. Across the
studies reporting the MLWHF questionnaire total
score up to 12 months follow-up, there was evidence of
a clinically important improvement with exercise
(random effects, 17 trials, 18 comparisons, n ¼ 1,995,
mean difference: 7.1; 95% CI:10.5 to 3.7) (very low
certainty) (Figure 2F). An improvement in MLWHF
score was also seen in the 3 trials (329 patients) that
reported total MLWHF score beyond 12months follow-
up (random effects mean difference: 9.5;
95% CI: 17.5 to 1.5) (low certainty) (Figure 2H).
Pooling studies regardless of outcome measurement
used showed that there may be a signiﬁcantimprovement in HRQoL with exercise at #12 months
follow-up (random effects, 26 trials, 29 comparisons,
3,833 patients: standardized mean difference
[SMD]: 0.60; 95% CI: 0.82 to 0.39) (GRADE: very
low certainty) (Figure 2G). GRADE rating was down-
grading due to high risk of bias and inconsistency.
For MLWHF up to 12 months follow-up, the TSA-
adjusted CI was 13.2 to 1.0 and 42.10 to 23.12 for
trials with longer follow-up (Online Table 3, Online
Figures 1.6b and 1.8a). Across all HRQoL outcomes
with conversion to MLWHF, mean difference: 1.7;
95% CI: 9.3 to 4.9 and TSA-adjusted CI was 9.9
to 4.3 (Online Figure 1.7b). Although the MLWHF
effect estimate of 7.1 favors ExCR and is larger than
the minimal important clinical difference of 5 points,
FIGURE 2 Continued
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699the TSA-adjusted CI is wide, diversity-adjusted
required information size was not reached, and
approximately 45% of the weight in analysis were
from trials at high risk of bias. TSA analysis of trials
at low risk of bias across different HRQoL scores
(Online Table 3, Online Figure 1.7c) present effect
estimates of mean differences: 4.72 TSA-adjusted
CI: 9.36 to 0.08.
A total of 18 of 31 comparisons (55%) reported sta-
tistical superiority (p < 0.05) in 1 or more HRQoL
domains for ExCR compared with control (Online
Appendix 6). No trials reported a lower HRQoL
domain score with ExCR than control.
SENSITIVITY ANALYSIS. Pooled outcomes for all-
cause mortality, hospital admissions, and HRQoL
were largely insensitive to exclusion of trials that
included patients with HF with diastolic or preserved
ejection fraction or the exclusion of the HF-ACTION
trial (Online Appendix 7).
METAREGRESSION. There were no differential treat-
ment effects across trial level characteristics and out-
comes in univariate metaregression, except for the
overall level of risk of bias and all-causehospitalization, MLWHF, and HRQoL outcomes
(Table 3). Trials at overall low risk of bias (low risk of
bias on $5 of 8 items) had evidence of a smaller ExCR
effect than trials at overall high risk of bias (low risk on
bias on <5 of 8 items), that is, all-cause hospitaliza-
tions (RR: 0.89; 95% CI: 0.67 to 0.96; vs. RR: 0.48;
95% CI: 0.34 to 0.68), MLWHF (mean difference: 5.0;
95% CI: 8.0 to 1.9; vs. mean difference: 15.0;
95% CI: 17.8 to 12.3), and all HRQoL (SMD: 1.00;
95% CI: 1.33 to 0.66; vs. SMD: 0.48;
95% CI: 0.70 to 0.27).
SMALL STUDY BIAS. There was no evidence of funnel
plot asymmetry, expect for all HRQoL measurements
(Egger test p value <0.0001) (Online Figure 2). This
asymmetry appeared to be due to an absence of
small- to medium-sized studies with poorer HRQoL
results for ExCR.
DISCUSSION
An updated systematic review and meta-analysis of
ExCR was conducted in adults with HF. This study
shows that, compared with no exercise control, ExCR
does not appear to reduce or increase mortality.
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700Potential differences were observed in the risk of
all-cause hospitalization and hospitalization due to
HF and improvements in HRQoL following exercise
interventions. In trials reporting MLWHF question-
naire scores, those undertaking ExCR may have better
disease-speciﬁc HRQoL by 7.1 points higher, on
average, than controls. This exceeds the reported
clinically important, meaningful difference of 5
points on the MLWHF questionnaire (15). These im-
provements in outcomes with ExCR were consistent
across trials regardless of the nature or type of pro-
gram (exercise only vs. comprehensive exercise; dose
of exercise intervention) and setting of the program
(center- vs. home-based) and other trial level char-
acteristics (length of follow-up, year of publication).
However, some of these outcome results are based on
low GRADE rating evidence and may be prone to bias.The TSA showed that for all clinical event outcomes,
the number of included patients remained too small
to draw deﬁnitive conclusions. However, the fact that
TSA of trials at low risk of bias showed an effect es-
timate for HRQoL close to a meaningful difference
indicates the importance of future high-quality trials
trials of ExCR collecting and reporting HRQoL
outcomes.
The present ﬁndings are broadly consistent with
the recently updated individual participant data
pooled analyses of the ExtraMATCH II (Exercise
Training Meta-Analysis of Trials for Chronic
Heart Failure; NCT03799354) collaborative group
(35,36). ExTraMATCH II reported that ExCR had no
impact on overall mortality (hazard ratio: 0.83;
95% CI: 0.67 to 1.04) and improved MLWHF (mean
of 5.9 points; 95% CI: 1.0 to 10.9). However, in
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701contrast to the present study, no reduction with
ExCR was found in either all-cause hospitalization
(hazard ratio of 0.90; 95% CI: 0.76 to 1.06) or HF-
speciﬁc hospitalization (hazard ratio of 0.98;
95% CI: 0.72 to 1.35). Although individual participant
data meta-analysis is recognized as the gold stan-
dard approach for assessing intervention subgroup
effects (37), this discrepancy in the impact of ExCR
on hospitalization may reﬂect limitations with the
analytic approach in this case. The ExTraMATCH II
authors highlighted 2 key limitations in their ana-
lyses; the ﬁrst was a lack of consistency in how
included trials deﬁned time-to-event outcomes; and
the second was that many included trials did not
collect patient data for the time-to-event outcomes
(35). The present ﬁndings are consistent with those
of other systematic reviews and meta-analyses of
randomized controlled trials (RCTs) of CR for HF
published since the 2014 version of the presentreview. Zhang et al. (38) collated trial-level data
from 2,533 patients with HF enrolled in 28 published
RCTs. Based on the MLWHF questionnaire re-
sponses, study authors reported a similar magnitude
of pooled improvement in HRQoL (mean: 6.8;
95% CI: 3.9 to 9.7; p < 0.0001). Similarly, based
on 8 RCTs including 317 participants with HF with
preserved ejection fraction, Chan et al. (39) reported
a pooled improvement in mean MLWHF score
of 6.8 (95% CI: 9.7 to 3.8; p < 0.0001) (39).
STUDY LIMITATIONS. The present authors believe
this is the most comprehensive systematic review of
aggregated data to date of randomized trial evidence
for the impact of ExCR for people with HF. This is the
ﬁrst version of this Cochrane review to incorporate a
formal assessment of quality by using GRADE rating
and TSA that can better control for type I and type II
errors of conventional meta-analysis methods. A
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702number of the new trials included in this update were
based on home-based ExCR models as opposed to the
conventional model groups of supervised center-
based ExCR provision. More evidence was identiﬁed
in patients with HF with preserved ejection fraction.
The general lack of reporting of methods in the
included trial reports made it difﬁcult to assess their
methodological quality and thereby judge their risk ofbias. Although larger HRQoL gains with ExCR were
associated with higher risk of bias, improvement in
HRQoL were still observed when meta-analyses were
carried out in trials at low risk of bias but now at or
under a minimal clinical important difference of 5
points. Funnel plot asymmetry for HRQoL is indica-
tive of small-study bias and signals possible publica-
tion bias.
FIGURE 2 Continued
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TABLE 3 Univariate Meta-Regression Analysis*
p Values
All-Cause Mortality at
6-12 Months Follow-Up
All Hospitalizations
at 6-12 Months Follow-Up
MLWHF at #12 Months
Follow-Up
All HRQoL Outcomes at
#12 Months Follow-Up
Type of ExCR† 0.72 0.55 0.22 0.49
Type of exercise‡ 0.93 0.06 0.15 0.66
Exercise dosek 0.10 0.44 0.89 0.71
Setting¶ 0.09 0.60 0.62 0.08
Single vs multicenter 0.46 0.60 0.09 0.06
Publication date 0.20 0.76 0.67 0.74
Risk of bias# 0.28 0.05 0.01 0.01
*Based on “Metareg” and “Permute” option in Stata software, correcting for multiple testing. †Exercise only vs. comprehensive. ‡Aerobic training alone vs. aerobic plus
resistance training. kNumber of weeks  number of sessions/week  average duration of session in hours. ¶Hospital only, home only, or both hospital and home. #Low risk of
bias on $5 of 8 items.
ExCR ¼ exercise-based cardiac rehabilitation; HRQoL ¼ health-related quality of life; MLWHF ¼ Minnesota Living with Heart Failure questionnaire.
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703CONCLUSIONS
The ﬁndings of this latest updated Cochrane sys-
tematic review support the beneﬁts of ExCR in terms
of probable reductions in the risk of all-cause and
HF-speciﬁc hospitalization and potential important
gains in HRQoL in people with HF. With inclusion of
more women, older patients, people with HF with
preserved ejection fraction in recent trials, and more
trials of ExCR delivered in a home-based setting, the
ﬁndings of this updated review have potentially
greater external validity and applicability. The ben-
eﬁts of ExCR appear to be consistent across trial
settings (i.e., center- compared to home-based
ExCR), type of rehabilitation (i.e., comprehensivecompared to exercise-only ExCR program), and dose
of ExCR.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Exercise-
based cardiac rehabilitation can improve the outcome of
patients with heart failure by reducing their risk of hos-
pital admission and by enhancing their quality of life.
TRANSLATIONAL OUTLOOK 1: Heart failure patients
should be routinely offered and encouraged to participate
in a cardiac rehabilitation program. Uptake of cardiac
rehabilitation is likely to be enhanced if patients can be
offered the choice of alternative models of provision that
include not only (conventional) center-based programs
but also home-based programs.
TRANSLATIONAL OUTLOOK 2: Additional research is
needed to better understand approaches to the improve
the uptake of longer-term adherence to cardiac rehabili-
tation of heart failure patients.
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